tirzepatide approved for osa Eli Lilly's gained FDA approval in December 2024 treating moderate-to-severe obstructive sleep apnea in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly Medscape | The FDA approved

Understanding Tirzepatide How it Works The dual-agents medication targeting both GIP and GLP-1 receptors results in an increased insulin secretion mechanism and better-than-single-action medications suppress appetite

In addition to providing long-term weight loss and possibly remission of T2DM, bariatric surgery is not feasible for large populations, has specific indications, and may result in surgical complications as well as other issues like malabsorption and micronutrient deficiencies

your doctor will assess existing conditions such as diabetes, cardiovascular disease, or thyroid issues, as these can influence the suitability of certain GLP-1 medications

Org Biomol Chem 2020 18, 3405-3422

GLP-1 medications require refrigeration

Your provider may recommend different tests depending on your health history, medications, symptoms, and treatment goals